Royalty Pharma plc
RPRX
$39.85
$0.320.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 5.29% | 1.83% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.29% | 1.83% | |||
| Cost of Revenue | 105.95% | -60.40% | |||
| Gross Profit | -23.70% | 12.54% | |||
| SG&A Expenses | -53.95% | 132.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -48.81% | 938.80% | |||
| Operating Income | 90.46% | -57.92% | |||
| Income Before Tax | 390.11% | -79.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 390.11% | -79.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -158.02% | 69.01% | |||
| Net Income | 855.12% | -87.34% | |||
| EBIT | 90.46% | -57.92% | |||
| EBITDA | 90.45% | -- | |||
| EPS Basic | 835.90% | -86.97% | |||
| Normalized Basic EPS | 82.17% | -59.65% | |||
| EPS Diluted | 838.50% | -86.99% | |||
| Normalized Diluted EPS | 86.81% | -59.69% | |||
| Average Basic Shares Outstanding | 1.98% | -2.75% | |||
| Average Diluted Shares Outstanding | -0.48% | -2.73% | |||
| Dividend Per Share | 0.00% | 0.00% | |||
| Payout Ratio | -0.89% | 6.72% | |||